Immatics to Present Key Updates at Upcoming Melanoma Event
Immatics Set for Major Presentation at Melanoma Congress
Immatics N.V. (NASDAQ: IMTX), a leading biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced an exciting upcoming oral presentation at the International Congress of the Society for Melanoma Research. This presentation will specifically highlight the updated clinical data for their promising cell therapy candidate, ACTengine® IMA203, which targets the preferentially expressed antigen in melanoma (PRAME).
Presentation Details
The oral presentation is scheduled for October 11, 2024, during the Plenary Session 1, which focuses on Developmental Immunotherapy including various innovative approaches. The time slot allotted is from 8:00 to 8:20 AM Central Daylight Time. Dr. Martin Wermke from the University Hospital Dresden, Germany, will lead the presentation, detailing the significant advancements in the treatment of PD1-refractory metastatic melanoma.
Understanding ACTengine IMA203
ACTengine® IMA203 is an autologous T cell product featuring a genetically modified T cell receptor designed to identify a specific HLA-A*02-presented peptide derived from PRAME. This peptide is notably prevalent in numerous solid tumors and is expressed at high levels within tumor cells. Immatics utilized its innovative XPRESIDENT® platform for mass spectrometry-based target discovery, enhancing the identification of this crucial target.
Currently, ACTengine® IMA203 is undergoing evaluation in a Phase 1 clinical trial, where it is being tested both as a monotherapy and in a second-generation variant (IMA203CD8). This innovative approach involves co-transducing IMA203-engineered T cells with a CD8?? co-receptor, allowing the therapy to tap into the strengths of both CD4+ and CD8+ T cell populations to combat cancer more effectively. Notably, Immatics has chosen to deprioritize the combination of IMA203 with immune checkpoint inhibitors, focusing on its standalone efficacy.
Company Vision and Commitment
Immatics is driven by its commitment to developing targeted cancer immunotherapies through meticulous target discovery and the engineering of potent T cell receptors. Their objective is to foster robust T cell responses against identified cancer targets, and this dedication lies behind the development of their promising pipeline of Adoptive Cell Therapies and TCR Bispecifics. Through strategic partnerships with leading pharmaceutical companies, Immatics aims to bring transformative therapies to patients facing cancer diagnoses.
Stay Updated with Immatics
Immatics plans to leverage its official website as a key channel for sharing non-public material information. Interested parties can also stay informed about company developments by following them on various social media platforms, including X, Instagram, and LinkedIn.
Contact Information
For media inquiries: Trophic Communications, Phone: +49 171 3512733, Email: immatics@trophic.eu
For investor relations: Jordan Silverstein, Head of Strategy, Immatics N.V., Phone: +1 346 319-3325, Email: InvestorRelations@immatics.com
Frequently Asked Questions
What is the focus of the presentation at the Congress?
The presentation will discuss updated clinical data for ACTengine® IMA203, targeting PRAME in metastatic melanoma.
Who will be presenting the data?
Dr. Martin Wermke from the University Hospital Dresden will present the findings at the congress.
When will the presentation take place?
The oral presentation is set for October 11, 2024, from 8:00 to 8:20 AM CDT.
What is the significance of ACTengine® IMA203?
ACTengine IMA203 represents a significant advancement in tailored cancer treatments, focusing on PRAME, which is expressed in many tumors.
How can I stay updated on Immatics' developments?
Follow Immatics on their social media platforms or visit their website for the latest news and updates.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.